RxDoctor Payments Data

Shyamasundaran Kottilil, MD

Infectious Disease · Baltimore, MDNPI 1891924619

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,560 of the $11,929 with a category attached, or 96.9%. Gilead accounts for 64.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $7,560 and has fallen 99.7% since, to $26 in 2025.

$11,929in general payments, 2019–2025

Across 9 payments — averaging $1325.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$8K
  • Merck$2K
  • Regeneron$2K
$168,773in research payments, 2019–2025

Across 6 payments — averaging $28,129 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$107K
  • Merck$62K

What the payments were for

  • Consulting fees$11,56097%
  • Travel & lodging$1501%
  • Food & beverage$1932%
  • Education$260%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead3$7,679
Merck5$2,375
Regeneron1$1,875

How this compares

$11,929 in reported general payments places this provider in the 85th percentile of 289 infectious disease providers in Maryland.

See all infectious disease providers in Maryland

Medicare billing

Part B allowed, 2024
$21,033
Medicare patients
61
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →